article thumbnail

Mira’s New Menopause Transitions Kit Allows for At-Home Hormone Monitoring

XTalks

Mira, a California-based women’s health technology company, has introduced its Menopause Transitions Kit, a new hormone monitoring kit designed for menopausal women. The at-home device enables women to track key hormone levels, offering real-time insights into the complex hormonal fluctuations associated with perimenopause and menopause.

Hormones 100
article thumbnail

New ‘Mechanical’ Weight Loss Pill from Oxford Medical Products Shows Positive Safety Data

XTalks

Oxford Medical Products has shared promising safety data from a first-in-human study for its ‘mechanical’ weight loss pill. Unlike drugs that alter metabolism or appetite by interacting with hormones, the pill functions entirely mechanically. Participants were either given Sirona or a placebo and monitored over a 12-week period.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New male contraceptive does not involve hormones

Medical Xpress

Instead of using hormones to disrupt sperm production, the new technique involves placing a hydrogel called ADAM into the vas deferens to prevent sperm from making its way to the urethra. A team of researchers at a company called Contraline has developed a new kind of male contraceptive.

Hormones 143
article thumbnail

Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin

Pharmaceutical Technology

Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare and serious condition, as well as for Childhood Onset Growth Hormone Deficiency (CGHD), if approved. It is a ghrelin agonist, an orally active small molecule that has been designed to stimulate the secretion of growth hormone from the pituitary gland.

Hormones 263
article thumbnail

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath

Fierce Pharma

After two delays, the FDA has finally signed off on Ascendis Pharma's hormone replacement therapy Yorvipath, also known as TransCon PTH, which is the first approved product for hypoparathyroidism in adults in the U.S. Ascendis Pharma should be well prepared for the U.S.

Hormones 108
article thumbnail

Neurocrine Biosciences’ Crenessity Approved as First New Treatment in Decades for Rare Genetic Disorder CAH

XTalks

CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. The most common form of CAH, 21-hydroxylase deficiency, disrupts hormone production, leading to cortisol deficiency and an overproduction of androgens.

Genetics 116
article thumbnail

Managing menopause: Hormone therapy is back

Medical Xpress

Hot flashes, night sweats and sleep disturbances are common symptoms of menopause that can affect health, quality of life and work productivity.